Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
The proposed study is a retrospective, non-interventional analysis that uses medical and pharmacy claims data in the US from Komodo Health.
Study data included adjudicated and paid medical and pharmacy claims in the US between November 1, 2017 and September 1, 2019 provided by Komodo Health.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
General Cohort
Adult (18 years or older)
Newly initiating on Aimovig (no other claims during a 180-day wash-in period)
Had continuous medical and pharmacy benefit eligibility from 180 days pre-index of Aimovig through 180-days post-index
Primary \& Secondary Objectives Sub-Cohort
\- Had 3 consecutive months with a claim for Aimovig (≤15 days gap between days supply and the subsequent claim to be considered consecutive)
Had continuous medical and pharmacy benefit eligibility from 180 days pre-index of Aimovig through 270-days post-index to permit assessment of cost outcomes (all-cause and migraine-related) during days 91-270 post-index
Had continuous medical and pharmacy benefit eligibility from 180 days pre-index of Aimovig to the maximum follow-up time post-index with continuous medical and prescription insurance eligibility until the data end date (September 1, 2019)
You may not be if
Patients with any claim for another CGRP-targeted medication (Ajovy or Emgality) during entire study period
Clareo Health | Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data
